These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34484294)

  • 1. Integrative Transcriptomic, Lipidomic, and Metabolomic Analysis Reveals Potential Biomarkers of Basal and Luminal Muscle Invasive Bladder Cancer Subtypes.
    Feng C; Pan L; Tang S; He L; Wang X; Tao Y; Xie Y; Lai Z; Tang Z; Wang Q; Li T
    Front Genet; 2021; 12():695662. PubMed ID: 34484294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the tumor-infiltrating immune repertoire in muscle invasive bladder cancer.
    Benítez R; Yu K; Sirota M; Malats N; Pineda S
    Front Immunol; 2023; 14():986598. PubMed ID: 36817478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer.
    Ochoa AE; Choi W; Su X; Siefker-Radtke A; Czerniak B; Dinney C; McConkey DJ
    Oncotarget; 2016 Dec; 7(49):80164-80174. PubMed ID: 27845906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.
    Kamoun A; de Reyniès A; Allory Y; Sjödahl G; Robertson AG; Seiler R; Hoadley KA; Groeneveld CS; Al-Ahmadie H; Choi W; Castro MAA; Fontugne J; Eriksson P; Mo Q; Kardos J; Zlotta A; Hartmann A; Dinney CP; Bellmunt J; Powles T; Malats N; Chan KS; Kim WY; McConkey DJ; Black PC; Dyrskjøt L; Höglund M; Lerner SP; Real FX; Radvanyi F;
    Eur Urol; 2020 Apr; 77(4):420-433. PubMed ID: 31563503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
    Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
    Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of miR-200c and miR141-Mediated lncRNA-mRNA Crosstalks in Muscle-Invasive Bladder Cancer Subtypes.
    Liu G; Chen Z; Danilova IG; Bolkov MA; Tuzankina IA; Liu G
    Front Genet; 2018; 9():422. PubMed ID: 30323832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mouse Models of Muscle-invasive Bladder Cancer: Key Considerations for Clinical Translation Based on Molecular Subtypes.
    Ruan JL; Hsu JW; Browning RJ; Stride E; Yildiz YO; Vojnovic B; Kiltie AE
    Eur Urol Oncol; 2019 May; 2(3):239-247. PubMed ID: 31200837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subclassification, survival prediction and drug target analyses of chemotherapy-naïve muscle-invasive bladder cancer with a molecular screening.
    Rinaldetti S; Rempel E; Worst TS; Eckstein M; Steidler A; Weiss CA; Bolenz C; Hartmann A; Erben P
    Oncotarget; 2018 May; 9(40):25935-25945. PubMed ID: 29899832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
    Tan TZ; Rouanne M; Tan KT; Huang RY; Thiery JP
    Eur Urol; 2019 Mar; 75(3):423-432. PubMed ID: 30213523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype.
    Rebola J; Aguiar P; Blanca A; Montironi R; Cimadamore A; Cheng L; Henriques V; Lobato-Faria P; Lopez-Beltran A
    Virchows Arch; 2019 Oct; 475(4):445-455. PubMed ID: 31240474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrating molecular subtype and CD8
    Li B; Jin K; Liu Z; Su X; Xu Z; Liu G; Xu J; Liu H; Chang Y; Wang Y; Zhu Y; Wang Z; Xu L; Zhang W
    Cancer Immunol Immunother; 2024 Mar; 73(4):66. PubMed ID: 38430246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences.
    de Jong JJ; Boormans JL; van Rhijn BWG; Seiler R; Boorjian SA; Konety B; Bivalacqua TJ; Wheeler T; Svatek RS; Douglas J; Wright J; Dall'Era M; Crabb SJ; Efstathiou JA; van der Heijden MS; Mouw KW; Miyamoto DT; Lotan Y; Black PC; Gibb EA; Porten SP
    Eur Urol Oncol; 2020 Aug; 3(4):420-423. PubMed ID: 32205136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Classification of Bladder Urothelial Carcinoma Using NanoString-Based Gene Expression Analysis.
    Lopez-Beltran A; Blanca A; Cimadamore A; Gogna R; Montironi R; Cheng L
    Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of bladder cancer subtypes in neurogenic bladder tumors.
    Manach Q; Cussenot O; Rouprêt M; Gamé X; Chartier-Kastler E; Reus C; Camparo P; Compérat E; Phé V
    Can J Urol; 2018 Feb; 25(1):9161-9167. PubMed ID: 29524970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative bioinformatics analysis of prognostic and differentially expressed genes in non-muscle and muscle invasive bladder cancer.
    Silva TA; Azevedo H
    J Proteomics; 2020 Oct; 229():103951. PubMed ID: 32860965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapies.
    Lang H; Béraud C; Cabel L; Fontugne J; Lassalle M; Krucker C; Dufour F; Groeneveld CS; Dixon V; Meng X; Kamoun A; Chapeaublanc E; De Reynies A; Gamé X; Rischmann P; Bieche I; Masliah-Planchon J; Beaurepere R; Allory Y; Lindner V; Misseri Y; Radvanyi F; Lluel P; Bernard-Pierrot I; Massfelder T
    Front Oncol; 2022; 12():930731. PubMed ID: 36033544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOXA1 Gene Expression for Defining Molecular Subtypes of Muscle-Invasive Bladder Cancer after Radical Cystectomy.
    Sikic D; Eckstein M; Wirtz RM; Jarczyk J; Worst TS; Porubsky S; Keck B; Kunath F; Weyerer V; Breyer J; Otto W; Rinaldetti S; Bolenz C; Hartmann A; Wullich B; Erben P
    J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32252315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New horizons in bladder cancer research.
    Boormans JL; Zwarthoff EC; Black PC; Goebell PJ; Kamat AM; Nawroth R; Seiler R; Williams SB; Schmitz-Dräger BJ
    Urol Oncol; 2020 Dec; 38(12):867-885. PubMed ID: 30852032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
    Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
    Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-Content Drug Discovery Targeting Molecular Bladder Cancer Subtypes.
    Rinaldetti S; Zhou Q; Abbott JM; de Jong FC; Esquer H; Costello JC; Theodorescu D; LaBarbera DV
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.